Epidemiological Study of Hospitalization Associated With Respiratory Syncytial Virus Infection in Taiwanese Children Between 2004 and 2007

Chi, Hsin; Chang, I‐Shou; Tsai, Fang‐Yu; Huang, Li‐Min; Shao, Pei-Lan; Chiu, Nan-Chang; Chang, Luan‐Yin; Huang, Fu‐Yuan

doi:10.1016/s0929-6646(11)60057-0

Cited by 42 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RSV infection has biennial pattern with peaks in spring and fall in northern Taiwan [22] but no significant seasonality in southern Taiwan [23]. Furthermore, based on the database of National Health Insurance in Taiwan, RSV related hospitalization occurs throughout the whole year with peaks in spring and fall, especially in prematurity and in patients with CHD [5]. In Taiwan, there is no exact “RSV season”.…”

Section: Discussionmentioning

confidence: 99%

“…In countries with temperate climates that have well defined RSV seasons, approximately 50% of RSV-related hospitalization occurs in infants younger than 6 months [3], [4]. In Taiwan, the population-based annual incidence of RSV-associated hospitalization was highest under 6 months of age and 70% of the patients with RSV-associated hospitalization are infants [5]. Predisposing conditions for the development of serious RSV disease include young age, prematurity, chronic lung disease (CLD), congenital heart disease (CHD), neuromuscular impairment, immunodeficiency, and Down syndrome [6], [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundRespiratory syncytial virus (RSV) circulates year round in Taiwan. A novel six consecutive monthly doses of palivizumab for RSV prevention protocol has been approved for high risk preterm infants since December 2010. This study aimed to determine the clinical effectiveness and safety of this novel protocol for the prevention of RSV infection.MethodsFrom April 2011 to March 2013, we enrolled infants born at ≤28 weeks gestation and infants born at ≤35 weeks gestation with chronic lung disease (CLD) who received palivizumab prophylaxis as study group and followed up for 12 months. Historic control, those who were born and followed up between July 2000 and June 2008, were retrieved for propensity score matching. Primary endpoint was RSV-related hospitalization, and secondary endpoints included the length of hospital stay and intensive care unit (ICU) care.ResultsWe enrolled 127 infants (108 infants born at ≤28 weeks and 19 infants born at 29–35 weeks with CLD). They completed 6-dose palivizumab as scheduled. Among the study group, the RSV-related hospitalizations were 2 (1.6%) within 6 months and 5 (3.9%) within 12 months after discharge. We matched 127 infants in the control group with 127 infants in the study group by propensity score matching. The reduction of RSV-related hospitalization rates were 86% (10.2% vs 1.6%, p = 0.002) within 6 months after discharge and 78% (15.7% vs 3.9%, p = 0.004) within 12 months after discharge. Compared to the control group, the rate of ICU care significantly decreased from 7.1% to 0.8% (p = 0.024) within 6 months after discharge and from 7.9% to 0.8% (p = 0.014) within 12 months after discharge. Adverse events were recorded in 6.4% injections.ConclusionsSix monthly intramuscular administration of palivizumab is effective for prevention of RSV hospitalization in regions with no single seasonal peak of RSV infection such as Taiwan.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…For children with bronchiolitis, García et al [57][58][59] found three predictors of ICU admission: virus species (RSV vs. non-RSV), atelectasis/condensation, and co-infection. For children with RSV infection, Verger et al [60][61][62][63][64][65][66][67][68] identified several risk factors for ICU admission: immature lung development, prematurity, chronic lung disease, congenital heart disease (defined as congestive heart failure, cyanosis, or pulmonary hypertension), neuromuscular impairment, high nasal RSV viral load, surfactant protein A2 polymorphism, age < 6 weeks, neurological disease, cerebral palsy, male gender, lung consolidation, lethargy, grunting, high arterial PaCO 2 , an ED visit in the past week, presence of moderate to severe retractions, inadequate oral intake upon presentation in the ED, and mental retardation.…”

Section: Predicting Icu Admissionmentioning

confidence: 99%

A systematic review of predictive modeling for bronchiolitis

Luo

Nkoy

Gesteland

et al. 2014

International Journal of Medical Informatics

View full text Add to dashboard Cite

Purpose: Bronchiolitis is the most common cause of illness leading to hospitalization in young children. At present, many bronchiolitis management decisions are made subjectively, leading to significant practice variation among hospitals and physicians caring for children with bronchiolitis. To standardize care for bronchiolitis, researchers have proposed various models to predict the disease course to help determine a proper management plan. This paper reviews the existing state of the art of predictive modeling for bronchiolitis. Predictive modeling for respiratory syncytial virus (RSV) infection is covered whenever appropriate, as RSV accounts for about 70% of bronchiolitis cases.Methods: A systematic review was conducted through a PubMed search up to April 25, 2014. The literature on predictive modeling for bronchiolitis was retrieved using a comprehensive search query, which was developed through an iterative process.Search results were limited to human subjects, the English language, and children (birth-18 years). Results:The literature search returned 2,312 references in total. After manual review, 168 of these references were determined to be relevant and are discussed in this paper. We identify several limitations and open problems in predictive modeling for bronchiolitis, and provide some preliminary thoughts on how to address them, with the hope to stimulate future research in this domain. Conclusions:Many problems remain open in predictive modeling for bronchiolitis. Future studies will need to address them to achieve optimal predictive models.

show abstract

“…El VSR presenta un patrón predictivo de enfermedad dentro de la comunidad han registrado epidemias en muchos países, incluyendo Australia [12], Reino Unido donde el pico de la epidemia corresponde a los meses fríos del año. En los Estados Unidos y Taiwán existe una variación estacional mayor en la cual el pico varía desde el otoño, invierno y principios de la primavera, el cual dura entre cuatro o cinco meses [4,15,16].…”

Section: Características Del Virusunclassified

“…Es muy bien conocido que el virus sincicial respiratorio (VSR) es la causa principal de la infecciones respiratorias más serias que ocurren en la infancia [4,5] …”

Section: Introductionunclassified

Infección respiratoria en niños por el virus sincicial respiratorio

Chaves

2014

Rev.Med.UCR

View full text Add to dashboard Cite

Resumen: Las infecciones respiratorias son las enfermedades más comunes en la infancia. Entre estas infecciones la bronquiolitis aguda se considera como el cuadro respiratorio más importante en niños menores de seis meses siendo el virus sinci un virus ARN con dos subtipos A y B los cuales están presentes en la mayoría de los brotes. El VSR presenta un patrón predictivo de enfermedad dentro de la comunidad. En Costa Rica es el r de la mayoría de internamientos en niños con enfermedad respiratoria y su incremento ocurre en los meses de setiembre a noviembre el cual coincide con la época lluviosa del año. Existen factores de riesgo que predisponen para una enfermedad más malformaciones congénitas del corazón, fumado en la familia, hacinamiento entre otros. Los niños con infección por VRS presentan tos, congestión nasal y sibilancias, el diagnóstico de laboratorio se realiza mediante cultivo, detección de antígeno de VSR por medio de inmunofluorescencia o técnicas moleculares. El tratamiento para la infección es de soporte, dándole importancia a la hidratación y a la oxigenación. Se ha utilizado ribavirina para aquellos niños que presenten en lavarse las manos frecuentemente ayuda a prevenir la diseminación de la infección tanto en la comunidad como a nivel hospitalario. El anticuerpo monoclonal Palivizumab ha mostrado ser efectivo en prevenir cuadros severos de infección causada por VSR. La mortalidad es menos del 1% y ocurre predominantemente en pacientes de alto riesgo. Los primero 1982 y 1983 en el Instituto de Investigaciones en S se demostró que el VSR es responsable de la mayoría de los casos de bronquiolitis en niños menores de cinco años. Las infecciones respiratorias son las enfermedades más comunes en la infancia. Entre estas infecciones la bronquiolitis aguda se considera como el cuadro respiratorio más importante en niños menores de seis meses siendo el virus sincicial respiratorio (VSR) el agente causal en el 80% de los casos. Es un virus ARN con dos subtipos A y B los cuales están presentes en la mayoría de los brotes. El VSR presenta un patrón predictivo de enfermedad dentro de la comunidad. En Costa Rica es el r de la mayoría de internamientos en niños con enfermedad respiratoria y su incremento ocurre en los meses de setiembre a noviembre el cual coincide con la época lluviosa del año. Existen factores de riesgo que predisponen para una enfermedad más severa como son la edad, género, malformaciones congénitas del corazón, fumado en la familia, hacinamiento entre otros. Los niños con infección por VRS presentan tos, congestión nasal y sibilancias, el diagnóstico de laboratorio se , detección de antígeno de VSR por medio de inmunofluorescencia o técnicas moleculares. El tratamiento para la infección es de soporte, dándole importancia a la hidratación y a la oxigenación. Se ha utilizado ribavirina para aquellos niños que presenten en lavarse las manos frecuentemente ayuda a prevenir la diseminación de la infección tanto en la comunidad como a nivel hospitalario. El anticuerpo monoclonal Palivizumab h...

show abstract

Epidemiological Study of Hospitalization Associated With Respiratory Syncytial Virus Infection in Taiwanese Children Between 2004 and 2007

Abstract: RSV infection occurs biennially with peaks in spring and fall in Taiwan. Patients with underlying diseases need longer hospital and ICU stays and incur higher medical costs. Younger age, prematurity, congenital heart disease and cerebral palsy are predictors of ICU care.

Cited by 42 publications

References 31 publications

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan

A systematic review of predictive modeling for bronchiolitis

Infección respiratoria en niños por el virus sincicial respiratorio

Contact Info

Product

Resources

About